Acyclovir (Zovirax) in herpetic disciform keratitis

L. M. T. COLLUM,1 P. LOGAN,1 and T. RAVENSCROFT2

From the 1Royal Victoria Eye and Ear Hospital, Dublin, and 2Wellcome Research Laboratories, Kent

SUMMARY Forty patients with disciform keratitis were randomly assigned to double-blind treatment with 3% acyclovir and 0.01% betamethasone drops or acyclovir and matching placebo. All patients who received the combination treated in a median time of 21 days, while 11 of 19 patients who received acyclovir alone were withdrawn because their condition remained static or worsened (p<0.001). The combination therapy produced a faster rate of healing (p=0.004); other clinical parameters also improved more favourably in the combination treatment group. Three patients had mild transient punctate keratopathy, but no serious adverse effects were seen despite treatment for a median duration of 28 days in the acyclovir group and 38 days in the combined therapy group. A combination of acyclovir and dilute steroid drops is effective in the management of disciform keratitis.

Acyclovir is an effective antiherpetic agent with a selective action in herpes infected cells.12 Since the first demonstration of a clinical antiviral effect in the eye3 acyclovir has been shown to be at least as effective4 or more effective5–8 than idoxuridine and adenine arabinoside9–9 and broadly equivalent to trifluorothymidine in the treatment of dendritic corneal ulceration.10 Therapy with acyclovir has been associated with a low incidence of mild, transient adverse effects, namely stinging and punctate keratopathy. Patients failing to respond to other antiviral agents have shown favourable clinical responses to acyclovir in open evaluation.11

Stromal keratitis is a more serious herpes infection of the cornea which has a longer clinical course and is often difficult to treat. Two forms of this infection can be recognised. Necrotising stromal keratitis, usually associated with and found under dendritic ulceration, is associated with significant corneal melting and a yellowish necrotic appearance. In this case it is almost certain that direct viral invasion occurs, causing the observed pathology. This should be distinguished from the disease referred to as disciform keratitis or oedema. It is different in appearance, and immune mechanisms probably play a significant part in its aetiology. Patients with disciform keratitis and iritis have been shown to have viral antigen in the white cells of the anterior chamber together with cell-free virus, although it has been difficult to culture virus from the aqueous humour.12 While the aetiology of disciform keratitis is unclear, it is known that small doses of corticosteroids will suppress and control the disease. However, the possible involvement of replicating virus suggests that an antiviral drug which can reach therapeutic levels in the aqueous humour should also be used.

While a combination of antiviral and steroids would seem to be the optimal therapeutic choice, it is important to determine whether an antiviral drug alone could offer a similar degree of therapeutic response, avoiding the problems associated with steroid use.

Acyclovir is a good candidate for the role as it is able to penetrate the intact corneal epithelium and stroma, achieving therapeutic levels in the aqueous humour, unlike other currently available antiviral agents.13 The current study was therefore undertaken to investigate the efficacy and safety of topical acyclovir alone or in combination with dilute steroid drops in the treatment of herpetic disciform keratitis.

Materials and methods

Forty patients with a clinical diagnosis of disciform keratitis were included in the study if they were able to attend regularly for follow-up. Informed consent to participation in the study was obtained from all patients or parents of patients as appropriate. Unicocular patients were excluded. Diagnosis was based on the history and clinical appearance of
patients; at all visits a full ocular examination was carried out. Patients were seen by the same 2 observers as often as clinically necessary but at least twice weekly during treatment.

All patients received 3% acyclovir ophthalmic ointment and in addition were randomly assigned to treatment with 0.01% betamethasone drops or a matching placebo in a double-blind manner. Treatment was applied to the infected eye 5 times daily. Patients also received 1% homatropine drops and the eye was not padded. If patients showed deterioration over the first 5 days or remained static for 14 days they were withdrawn from the study and treated with an alternative antiviral and a dilute steroid preparation in the usual manner. The keratitis was regarded as healed when the corneal thickness had returned to normal, when epithelial and stromal oedema had regressed, when endothelial deposits were either old in appearance or had disappeared, and when there was no more activity of any kind in the anterior chamber. Corneal thickness was measured with a pachometer attached to the Haag-Streit slit-lamp. Symptoms of pain, photophobia, lacrimation, and grittiness were scored at each visit on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). A record was made of any adverse events potentially attributable to treatment, including assessment of intraocular pressure.

The t test was used to compare treatment groups for age, initial 38.9±3.99 40.3±3.57

Corneal thickness 2.11±0.215 2.25±0.204

Uveitis: flare 1.11±0.186 0.76±0.153

Grittiness 0.84±0.175 0.62±0.146

Photophobia 0.79±0.244 0.55±0.211

Lacrimation 0.95±0.223 0.90±0.161

Duration of symptoms 1.47±0.280 1.55±0.235

P 1.26±0.290 0.75±0.260

Table 1 Patient demography

\( P = 0.004 \)

Fig. 1 Cumulative healing rate for patients with disciform keratitis. (Betnesol = betamethasone).

\( \text{ACV + BETNESOL (n = 21)} \)

\( \text{ACV + PLACEBO (n = 19)} \)

difference (\( p<0.001 \), Fisher’s exact test). To avoid possible bias due to the problems associated with withdrawal of steroid therapy in these patients the analysis was repeated after exclusion of 3 patients in the combined therapy group and 5 patients in the group which received acyclovir alone who were receiving steroids at entry. The remaining 18 recipients of the combined therapy who were not receiving steroids at entry healed, while 6 of 14

Results

Nineteen patients were treated with acyclovir and placebo while 21 received acyclovir and dilute steroid drops. Demographic comparison of the treatment groups showed no significant differences at the 10% level (2-tailed test), except the proportion who had previous antiviral therapy for the current attack (\( p = 0.058 \)). Four of the acyclovir plus placebo group and 5 of the acyclovir plus steroids group had received steroids for previous attacks. These results are presented in Table 1.

All patients who received acyclovir and steroids healed in a median time of 21 days, while 11 of 19 patients who received acyclovir and placebo were withdrawn from the study (Fig. 1), a highly significant
Acyclovir (Zovirax) in herpetic disciform keratitis

Table 2  Progression of corneal thickness and uveitis

<table>
<thead>
<tr>
<th></th>
<th>Acyclovir+</th>
<th>Acyclovir+</th>
</tr>
</thead>
<tbody>
<tr>
<td>placebo</td>
<td>betamethasone</td>
<td></td>
</tr>
<tr>
<td>(n=19)</td>
<td>(n=21)</td>
<td></td>
</tr>
<tr>
<td>Corneal thickness: same</td>
<td>8*</td>
<td>1*</td>
</tr>
<tr>
<td>better</td>
<td>8</td>
<td>20</td>
</tr>
<tr>
<td>worse</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Uveitis: same (flare/cells)</td>
<td>11/12</td>
<td>0/0</td>
</tr>
<tr>
<td>better (flare/cells)</td>
<td>7/5</td>
<td>21/21</td>
</tr>
<tr>
<td>worse (flare/cells)</td>
<td>1/1</td>
<td>0/0</td>
</tr>
</tbody>
</table>

*One patient normal at entry.

recipients of acyclovir and placebo who had not received steroids at entry failed to respond (p<0.007, Fisher's exact test). Of the 14 acyclovir and placebo recipients 2 had a history of steroid treatment for previous attacks. One of these healed while the other failed to respond.

In addition the rate of healing was analysed for the groups and compared by logrank analysis. Patients receiving acyclovir and steroids healed at a significantly faster rate (p<0.004).

Clinical parameters which tend to be responsive to steroid therapy include uveitis and corneal thickness. The improvement in both of these parameters by the end of therapy was particularly marked in the group which received acyclovir and betamethasone. A formal analysis of these parameters was not possible because of the large proportion of acyclovir and placebo recipients who were withdrawn before they healed. From the results presented in Table 2 it can be seen that all patients who received acyclovir and betamethasone had returned to normal. In the group which received acyclovir and placebo 3 patients had increased corneal thickness and one had more severe uveitis at the end of therapy.

Twenty-seven of the 40 patients included in the study had a visual acuity less than 6/18 (Table 3). The change in visual acuity during therapy was similar for both groups. However, visual acuity worsened in 4 recipients of acyclovir and placebo and one recipient of acyclovir and betamethasone.

Symptoms of pain, photophobia, lacrimation, and grittiness had completely resolved in 20 of 21 acyclovir and betamethasone recipients. In contrast, only 9 of 19 acyclovir and placebo treated patients had a similar response, but it should be kept in mind that a large proportion of these patients left the study with active disciform keratitis.

Treatment continued for an average of 28 days in the acyclovir and placebo group and an average of 38 days in the acyclovir and betamethasone group. The only adverse event recorded was mild, transient punctate keratopathy in 3 patients.

Discussion

This clinical trial has provided a clear demonstration of the need for a combination of antiviral agent and steroid in the management of disciform keratitis. It is widely accepted that steroids alone cannot be used to treat this herpetic infection because of the danger of further or enhanced virus activity. The 8 patients who responded to acyclovir alone may represent the proportion of cases which might be expected to make a full recovery, in the absence of further virus activity, without therapeutic intervention.

It is unfortunate that in these patients it is not possible to avoid the use of steroid therapy and the problems associated with it. However, acyclovir combined with 0.01% betamethasone drops has shown to produce a rapid and consistent clinical response with virtually no adverse effects. We therefore conclude that acyclovir combined with steroids is more effective than acyclovir alone, and that acyclovir without concomitant steroids does not provide effective control of disciform keratitis.

We thank Mrs C. Burke, medical statistician, Wellcome Research Laboratories, for carrying out the statistical analysis of this clinical trial.

Table 3  Visual acuity

<table>
<thead>
<tr>
<th></th>
<th>Acyclovir+</th>
<th>Acyclovir+</th>
</tr>
</thead>
<tbody>
<tr>
<td>placebo</td>
<td>betamethasone</td>
<td></td>
</tr>
<tr>
<td>(n=19)</td>
<td>(n=21)</td>
<td></td>
</tr>
<tr>
<td>Visual acuity at presentation:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6/60</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>6/60</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>6/18</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>6/9</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>Change in visual acuity after therapy:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Same</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>Better</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>Worse</td>
<td>4</td>
<td>1</td>
</tr>
</tbody>
</table>

References

Acyclovir (Zovirax) in herpetic disciform keratitis.

L M Collum, P Logan and T Ravenscroft

doi: 10.1136/bjo.67.2.115

Updated information and services can be found at:
http://bjo.bmj.com/content/67/2/115

These include:

Email alerting service
Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/